Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00611767 · ClinicalTrials.gov registry record · NA

GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence

A NA study of Alcoholism, sponsored by Yale University.

Completed
Registry status
NA
Development phase
73
Enrollment target
1
Study location

NCT00611767 is a NA study of Alcoholism that has completed, run by Yale University. The registered enrollment target is 73 participants, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00611767, a NA study of Alcoholism, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
73 participants
Enrollment target
1
Study location

Study Summary

This Project will explore the hypothesis that individuals with a family history positive for alcohol dependence (without any current Axis I disorder, except nicotine dependence), experience an alteration in the reward "valence" (balance of positive and negative effects) of the GABAA receptor agonist barbiturate (thiopental) compared to family history negative age-matched subjects. Further, variation in genes involved in brain GABA function may influence the risk for alcoholism by altering a component of the discriminative stimulus effects of ethanol.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Thiopental

Study Locations (1)

Connecticut

  • VA Connecticut Healthcare System - West Haven

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2005-11
Est. Completion 2012-04
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT00611767

The ClinicalTrials.gov registry entry for NCT00611767 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (80% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00611767 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT00611767 about?

NCT00611767 is a clinical study titled "GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence". This Project will explore the hypothesis that individuals with a family history positive for alcohol dependence (without any current Axis I disorder, except nicotine dependence), experience an alteration in the reward "valence" (balance of positive and negative effects) of the GABAA receptor agonist...

What is the current status of trial NCT00611767?

This trial is currently completed. It is a NA study. The enrollment target is 73 participants. The study started on 2005-11. Estimated completion is 2012-04.

What conditions does trial NCT00611767 study?

This clinical trial studies the following conditions: Alcoholism.

What interventions are being tested in trial NCT00611767?

The interventions under investigation include: Placebo (DRUG), Thiopental (DRUG).

Who is sponsoring clinical trial NCT00611767?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00611767 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcoholism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.